

**Remarks:**

The above-captioned application, which is filed concurrently with this Preliminary Amendment is submitted further to the Examiner's restriction requirement issued for U.S. Patent Application Ser. No. 10/161,816, of which the above-captioned application is a divisional application. The specification has been amended to disclose that the above-captioned application is a divisional application of U.S. Patent Application Ser. No. 10/161,816, filed June 4, 2002, which is a divisional of U.S. Patent Application Ser. No. 09/587,007, filed June 5, 2000, which claims priority to U.S. Provisional Patent Application Ser. No. 60/151,183, filed August 27, 1999


The claims have been amended to cancel Claim 2, to amend Claims 1 and 5 to be directed to the treatment of depression, and to amend Claim 4 to be directed to a limited number of compounds. Claims 1 and 3-10 are now pending in the application.

Please charge the extension fee and any other appropriate fee to cover this submission to Pfizer Deposit Account No. 16-1445. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

Date: \_\_\_\_\_

10/1/2003

  
\_\_\_\_\_  
Andrea Dorigo  
Attorney for Applicant(s)  
Reg. No. 47,532

Pfizer, Inc.  
Patent Department, 5th Floor  
150 East 42nd Street  
New York, NY 10017-5755  
(212) 733-1898